Navigation Links
Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting
Date:5/18/2011

tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is currently approved in 100 countries.

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators.

Important Safety Considerations For Patients Taking Nexavar

Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer

Nexavar may cause fetal harm when administered to a pregnant woman. Women of childbearing potential are advised to avoid becoming pregnant and female patients should also be advised against breastfeeding while receiving Nexavar

Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction

Gastrointestinal perforation was an uncommon adverse reaction and has been reported in less than 1% of patients taking Nexavar

Uncommon but serious adverse reactions, including keratoacanthomas/squamous cell cancer of the skin and Stevens-Johnson Syndrome, have been reported in clinical trials

An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider discontinuation of Nexavar

Hypertension may occur early in the course of treatment. Monitor blood pressure weekly during the first 6 weeks and periodically thereafter and treat, as required

Hand-foot skin reaction and rash are common and management may include topical therapies for symptomatic relief. In cases of any severe or persistent adve
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
2. Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
3. Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
4. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
5. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
6. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
7. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
8. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
9. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
10. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
11. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 With advancements in neurological and ... is seeing new growth, according to Kalorama Information. ... for the majority of market volume, newer 3T ... which are creating opportunities for more sophisticated applications. The ... at a rate of 4%, with world market ...
(Date:12/17/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" ... offering of $125 million aggregate principal amount of 3.75% ... were offered and sold only to qualified institutional buyers ... 1933, as amended (the "Securities Act"). The ... per year, payable semiannually in arrears on June 15 ...
(Date:12/15/2014)... 15, 2014 Registreer nu via  ... und 20. Februar sind alle akkreditierten pharmazeutischen ... ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, der ... die neue profitablen Unternehmensdienstleistungen, die für Apotheken ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... Conference call webcast Monday, 5:00 p.m. EDT and ... and http://www.isispharm.com , MELBOURNE, Australia ... (ASX: ANP) and Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ... the ATL/TV1102 Phase IIa clinical trial in patients ...
... BENEFIT is first and only prospectively planned 5-year study to ... lasting ... Bayer HealthCare Pharmaceuticals,announced today that new data from its BENEFIT ... that early,initiation of Betaseron(R) (interferon beta-1b) treatment in patients with,a ...
Cached Medicine Technology:ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis 2ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis 3ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis 4ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis 5ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis 6ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis 7Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS 2Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS 3Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS 4Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS 5
(Date:12/21/2014)... Downey, CA (PRWEB) December 21, 2014 The ... toy drive in the Santa Ana and Whittier offices. The ... help brighten the lives of patients and their families during ... to reach out to approximately 70 children between both offices. ... With the help of Target’s community service team, store managers ...
(Date:12/20/2014)... a distinguished special dress supplier, has just done something ... cut prices to all its prom dresses already, offering ... Many of the hottest styles are sold here like ... more. , A spokesman for MissyDress says, “The great ... prom dresses or sweetheart chiffon prom dresses, you will ...
(Date:12/20/2014)... DePuy Pinnacle hip lawsuits ( ... the artificial hip system was defectively designed continue ... Bernstein Liebhard LLP reports. According to an Order ... on December 2nd, counsel in 10 DePuy Pinnacle ... on November 19, 2014, with depositions to conclude ...
(Date:12/20/2014)... Office Urgent Care of Paramus, New Jersey has served the ... treated over 40,000 patients while carrying out their mission of ... Paramus area. , For 2015, the practice is proud ... board certified physicians: Christine Milosis MD, Sandra Ugras Rey DO, ... work tirelessly to carry out The Doctor’s Office Urgent ...
(Date:12/20/2014)... The aftermath of the November 24th hack on ... in Hollywood, but worldwide. As reported in the ... that attack are starting a finger-pointing game which could put ... they are not the only ones affected, regular employees who ... embarrassing times ahead, agents and lawyers could be in for ...
Breaking Medicine News(10 mins):Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5
... has been selected for the Physician of the Year Award by ... surgeon director in Otolaryngology at the same Infirmary, will be presented ... Nov 20 in New York., ,Mehta graduated in medicine from ... He has been affiliated with the Infirmary for more than 25 ...
... 50 percent of the clan is found battling chronic skin ... new study has claimed that nearly 50,000 hair stylists are ... shampoos that render constantly moist hands., ,Due to this, ... on with their jobs when the condition worsens. Hairdressers are ...
... more salt than the deep blue sea, according to a ... brings about a dramatic reduction in their blood pressure which ... disease and stroke later in life. ,The report states ... Twirls contain more than twice as much salt as the ...
... that although very difficult to disseminate actual figures it ... of the funds allocated for the disbursement of medicines ... or lost because of fraudulent practices, bribery and diversion ... assessed that governments spent about US$50 billion (€39 billion) ...
... killer H5N1 avian flu virus that had emerged in early ... resistant to the vaccination programme and might even be aided ... wave of transmission of H5N1 avian flu and could potentially ... of the Proceedings of National Academy of Sciences. ,The ...
... regularly, because the size of your paunch is directly related ... new research conducted by a medical expert of Indian origin. ... University of Leicester, obesity has now become a worldwide epidemic. ... currently over half of women and two-thirds of men in ...
Cached Medicine News:Health News:Hair-raising issues of hairdressers 2Health News:Kids' Food: Saltier than the Deep Blue Sea 2Health News:Kids' Food: Saltier than the Deep Blue Sea 3Health News:Kids' Food: Saltier than the Deep Blue Sea 4
... dimeglumine) is a paramagnetic MRI contrast agent. ... gadobenate, a chelating agent that forms a ... ion. It is salified with meglumine forming ... all the physico-chemical features typical of gadolinium ...
... OMNISCAN was launched in the U.S. ... the central nervous system (CNS) to detect ... associated tissues. OMNISCAN has since received approval ... and pediatric CNS and body indications. OMNISCAN ...
... dimeglumine) injection was introduced in 1988, it ... magnetic resonance imaging (MRI). It became the ... MRI. Today, the product is still a ... neck and body. MAGNEVIST is used in ...
... in 1996, VISIPAQUE is the only isosmolar contrast ... osmolality equal to that of blood, VISIPAQUE was ... also the only contrast medium formulated with sodium ... In 1997, VISIPAQUE received FDA approval for use ...
Medicine Products: